title: Post-transplantation lymphoproliferative disease in Chinese: the Queen Mary Hospital experience in Hong Kong.
abstract: Post-transplantation lymphoproliferative disease (PTLD) is an unique iatrogenic complication after bone marrow transplantation (BMT) and solid organ transplantation (SOTx). The pattern of EBV related lymphoma in Chinese is different from Caucasians. We surveyed the incidence, clinical and pathological spectrum of PTLD among 541 cases of allogeneic BMT, 145 cases of renal transplant, 35 cases of heart/lung transplantation and 146 cases of orthotopic liver transplantation (OLT). From 1994 to 2001, 13 consecutive cases of PTLD were diagnosed, ranging from disseminated NK cell lymphoma to localized plasmacytoma. Both donor and recipient derived PTLD was documented. Disease was often heralded by cytomegaloviral disease and antithymocyte globulin (ATG) usage. Two cases were diagnosed post-mortem, and six patients died of PTLD at a median of 3 months. Complete and partial remission was only achieved in 3 and 2 cases, respectively, despite a range of treatment (reduced immunosuppression, explantation, radiotherapy, combination chemotherapy, donor lymphocytes, autologous marrow infusion and rituximab). Most responding patients died subsequently of rejection, infection and graft versus host disease (GVHD). The incidence of PTLD is not increased in Chinese patients. However, some patients may be at increased risk, especially mismatched allogeneic BMT, parental OLT (especially involving young infants) and heavy ATG exposure.
authors.affiliation: The University Department of Medicine, Queen Mary Hospital, University of Hong Kong, Peoples' Republic of China. auwing@hotmail.com
authors.forename: W Y
authors.initials: WY
authors.lastname: Au
authors.forename: A K W
authors.initials: AK
authors.lastname: Lie
authors.forename: Y L
authors.initials: YL
authors.lastname: Kwong
authors.forename: T W
authors.initials: TW
authors.lastname: Shek
authors.forename: B R
authors.initials: BR
authors.lastname: Hawkins
authors.forename: K N
authors.initials: KN
authors.lastname: Lai
authors.forename: S C W
authors.initials: SC
authors.lastname: Tang
authors.forename: C M
authors.initials: CM
authors.lastname: Lo
authors.forename: S T
authors.initials: ST
authors.lastname: Fan
authors.forename: C L
authors.initials: CL
authors.lastname: Liu
authors.forename: G C F
authors.initials: GC
authors.lastname: Chan
authors.forename: E M C
authors.initials: EM
authors.lastname: Chau
authors.forename: S W
authors.initials: SW
authors.lastname: Chiu
authors.forename: R
authors.initials: R
authors.lastname: Liang
mesh_terms: D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D003586:Cytomegalovirus Infections / Q000150:complications / Q000209:etiology; D016208:Databases, Factual; D005260:Female; D006801:Humans; D007223:Infant; D008232:Lymphoproliferative Disorders / Q000453:epidemiology / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D016377:Organ Transplantation / Q000009:adverse effects / Q000401:mortality; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects* / Q000276:immunology; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum